Pharvaris N.V. Ordinary Shares (PHVS)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Pharvaris as a clinical-stage biotech, not a proven business. It is developing deucrictibant, a small-molecule B2-receptor antagonist for rare bradykinin-mediated angioedema, including HAE and AAE-C1INH; the asset is in phase 3. That gives it a possible high-value niche, but no durable moat until approval and revenue are proven. The financials are those of a cash-consuming research operation. At the 2026-10-13 close of $30.02, FairStock calculates a market cap of $1.9B, P/B of 6.11, and P/E of -10.14. ROE is -70.46% and ROCE is -42.32%, so capital is being consumed rather than compounded. Trailing-twelve-month free cash flow is -$155.3M, and FairStock's FCF yield is -8.3%. The Piotroski F-Score is only 2/9. The one clear balance-sheet positive is D/E of 0.00, with an Altman Z-Score of 38.55, though for a clinical-stage biotech that mostly reflects no debt rather than safety of the pipeline. FairStock Score is 20/100. The Lynch category is none because only 0 years of filed results exist and three are needed. Growth is not yet visible in revenue; the company remains dependent on phase 3 readouts and regulatory decisions. Graham would demand a margin of safety; here the price is a bet on future approval, not on present earnings. Buffett would ask whether the science is understandable and durable. The rare-disease focus is understandable, but without approved product economics, the moat and intrinsic value are unproven. The key variables are cash burn and trial data, not short-term price.

In plain English: Pharvaris is a late-stage biotech company developing a treatment for rare swelling disorders called angioedema. The business is not yet profitable, pays no dividend, and is burning cash, so it depends on clinical trial success. At $30.02, the price looks expensive compared with its current financial numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer